Short answer
Kymera Therapeutics, Inc. (KYMR) filed an 8-K current report with the SEC on June 8, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). COO Jeremy Chadwick resigned June 5, 2026, citing personal reasons rather than disagreement with Kymera’s practices or policies.
Kymera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- COO Jeremy Chadwick resigned June 5, 2026, citing personal reasons rather than disagreement with Kymera’s practices or policies
- Chadwick remains a company advisor through November 2026, supporting leadership transition continuity
- COO vacancy creates near-term execution and succession risk for Kymera’s operations function
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kymera Therapeutics, Inc. 8-K filings
Get the next KYMR 8-K as it lands
Follow KYMR for push alerts, or ask the research agent what this filing means.